143 related articles for article (PubMed ID: 8893875)
1. Gemcitabine: a case study for clinical benefit.
Von Hoff DD
Semin Oncol; 1996 Oct; 23(5 Suppl 10):1-2. PubMed ID: 8893875
[No Abstract] [Full Text] [Related]
2. Introduction. Gemcitabine: ten years of clinical experience.
Cartei G; Labianca R
Ann Oncol; 2006 May; 17 Suppl 5():v5-6. PubMed ID: 18309538
[No Abstract] [Full Text] [Related]
3. Gemcitabine: we've reached the end of the beginning.
Green MR
Semin Oncol; 1996 Oct; 23(5 Suppl 10):99-100. PubMed ID: 8893890
[No Abstract] [Full Text] [Related]
4. [Gemcitabine and pemetrexed update].
Spano JP; Bay JO
Bull Cancer; 2007; 94 Spec No Actualites():S83. PubMed ID: 17845975
[No Abstract] [Full Text] [Related]
5. [Gemcitabine: Applications and perspectives].
Tumori; 1997; 83(5):877-80. PubMed ID: 9446252
[No Abstract] [Full Text] [Related]
6. Gemcitabine: ten years of clinical experience. Proceedings of a workshop. September 19-21, 2005. Monastier di Treviso, Italy.
Ann Oncol; 2006 May; 17 Suppl 5():v5-200. PubMed ID: 18309567
[No Abstract] [Full Text] [Related]
7. Gemcitabine: novel combination of efficacy and tolerability.
Anticancer Drugs; 1993 Dec; 4(6):671. PubMed ID: 8298167
[No Abstract] [Full Text] [Related]
8. [MMW drug award for gemcitabine. Cytostatic drug with growing indications].
Füessl HS
MMW Fortschr Med; 2006 Nov; 148(45):6-7. PubMed ID: 17615737
[No Abstract] [Full Text] [Related]
9. Gemcitabine hydrochloride: combination of activity and tolerability. Proceedings of a symposium. Jerusalem, Israel, November 14, 1993.
Anticancer Drugs; 1995 Dec; 6 Suppl 6():5-65. PubMed ID: 8718418
[No Abstract] [Full Text] [Related]
10. Gemcitabine--a major advance?
Thomas A; Steward WP
Ann Oncol; 1998 Dec; 9(12):1265-7. PubMed ID: 9932153
[No Abstract] [Full Text] [Related]
11. Clinical and preclinical activity of 2',2'-difluorodeoxycytidine (gemcitabine).
Lund B; Kristjansen PE; Hansen HH
Cancer Treat Rev; 1993 Jan; 19(1):45-55. PubMed ID: 8431926
[No Abstract] [Full Text] [Related]
12. Evolving considerations in the design and interpretation of phase I trials investigating gemcitabine based chemoradiotherapy regimens.
McGinn CJ
Cancer J; 2002; 8(3):239-41. PubMed ID: 12074322
[No Abstract] [Full Text] [Related]
13. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of gemcitabine for the treatment of pancreatic cancer.
Ward S; Morris E; Bansback N; Calvert N; Crellin A; Forman D; Larvin M; Radstone D
Health Technol Assess; 2001; 5(24):1-70. PubMed ID: 11701098
[No Abstract] [Full Text] [Related]
14. Efficacy of gemcitabine in the treatment of patients with gallbladder carcinoma: a case report.
Gallardo J; Fodor M; Gamargo C; Orlandi L
Cancer; 1998 Dec; 83(11):2419-21. PubMed ID: 9840543
[No Abstract] [Full Text] [Related]
15. New drugs for cancer.
Lippman AJ
N J Med; 1998 Jul; 95(7):51-4. PubMed ID: 16013168
[No Abstract] [Full Text] [Related]
16. Gemcitabine for pancreatic cancer: how hard to look for clinical benefit? An American perspective.
Gelber RD
Ann Oncol; 1996 Apr; 7(4):335-7. PubMed ID: 8805922
[No Abstract] [Full Text] [Related]
17. Pharmacogenetics and pharmacoepigenetics of gemcitabine.
Candelaria M; de la Cruz-Hernández E; Pérez-Cárdenas E; Trejo-Becerril C; Gutiérrez-Hernández O; Dueñas-González A
Med Oncol; 2010 Dec; 27(4):1133-43. PubMed ID: 19902390
[TBL] [Abstract][Full Text] [Related]
18. Unusual response to gemcitabine in a case of peritoneal malignant fibrous histiocytoma.
Hitt R; Jimeno A; Castellano D; Cortés-Funes H
Anticancer Drugs; 2003 Sep; 14(8):663-4. PubMed ID: 14501390
[No Abstract] [Full Text] [Related]
19. Clinical benefit as a primary efficacy endpoint.
Ballatori E; Del Favero A; Roila F
J Clin Oncol; 1998 Feb; 16(2):803-4. PubMed ID: 9469377
[No Abstract] [Full Text] [Related]
20. H-gemcitabine: a new gemcitabine prodrug for treating cancer.
Dasari M; Acharya AP; Kim D; Lee S; Lee S; Rhea J; Molinaro R; Murthy N
Bioconjug Chem; 2013 Jan; 24(1):4-8. PubMed ID: 23237198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
